Press Release: BB Biotech AG with after-tax loss in the first half year of 2016

BB Biotech AG / BB Biotech AG with after-tax loss in the first half year of 2016 . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the first half year of 2016.

Based on preliminary unaudited consolidated results, BB Biotech AG closed the first half year of 2016 with a loss of CHF 1.17 billion (CHF 717 million profit in the corresponding period of the previous year).

BB Biotech's share price decreased 18.8% in CHF and 18.4% in EUR during the corresponding period.

Biotechnology stocks and BB Biotech AG's portfolio stabilized in the second quarter of 2016. BB Biotech earned an after-tax profit of CHF 36 mn in the second quarter (profit of CHF 337 mn in prior-year period). As an investment company, the results reflect the performance of the stocks it holds in its investment portfolio.

The interim report as of June 30, 2016 will be published on July 22, 2016.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland

Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Press release: http://hugin.info/130285/R/2027698/753612.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: BB BIOTECH AG via Globenewswire

HUG#2027698

--- End of Message ---

BB BIOTECH AG

Schwertstrasse 6 Schaffhausen Switzerland

WKN: AONFN3;ISIN: CH0038389992;

http://www.bbbiotech.ch/ (END) Dow Jones Newswires

   July 11, 2016 12:10 ET (16:10 GMT)- - 12 10 PM EDT 07-11-16